FGF inhibitors may provide a new way to treat high blood pressure
Drugs designed to halt cancer growth may offer a new way to control high blood pressure...
List view / Grid view
Drugs designed to halt cancer growth may offer a new way to control high blood pressure...
24 May 2017 | By Niamh Marriott, Junior Editor
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK treatments in Europe...
6 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Kitov Pharmaceuticals a waiver related to the $2,038,100 new drug application filing fee for KIT-302...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The discoveries include DNA changes in three rare genes that have much larger effects on blood pressure in the population than previously seen, providing new insights into the physiology of hypertension and suggesting new targets for treatment...
7 June 2016 | By Victoria White, Digital Content Producer
Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US...